skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: I have had a nice pop on this stock(FTG Firan).Can you give me some advise going forward.Thanks
Read Answer Asked by Don on March 31, 2015
Q: I wonder if you can comment on the latest earnings report from Savaria. It would seem to warrant a more positive share price reaction.
Read Answer Asked by robert on March 30, 2015
Q: After experiencing healthy gains in Patient Home Monitoring, I read through the entire Convalo Health website to learn about their company. Their plans has some good potential but seems to rely heavily on new insurance-paid therapies. If the Republicans win the next election and skewer Obama's healthcare plan, will this significantly affect Convalo's business model? Second, they presently have one location where they have increased sales from $80K to $300K and around $5M in cash. I assume they will have to do a "healthy" raise to grow similar to PHM.
Your analysis would be appreciated.
Thanks.
Read Answer Asked by Steven on March 30, 2015
Q: The last question on DDC was Nov 13/13, at which time you called it an OK - type of company. It appears since then to have changed for the better. Certainly it is doing better than most of its peers. Thru my bank acct I have access to Value Engine analysis of DDC. According to them DDC's fair market value is $37. So I'm thinking this may be a good buy. I'm not sure how to interpret their balance sheet, however There is no line that says "debt" - just a comparison of Assets to Liabilities; which to my untrained eyes looks pretty good(assets=3x liabilities).So what are the debt issues, if any with this company? Are there any other red flags I should be aware of? Lastly, how do view DDC today.
Thankyou----I really enjoy your service.
Read Answer Asked by Lionel on March 30, 2015
Q: I'm up over 300%. It was a very conservative buy in the first place, so even with gain, it is a reasonable position in my portfolio. I read a report this weekend that they may not be completely forthcoming with their income statement, that Net Operating Profit in Q1 2015 was listed as $1.572 million, but the fine print indicated that this figure excluded the amortization of intangible assets, stock-based compensation, the gain or loss on derivative financial liability, interest expense, and income tax expense. With the inclusion of these expenses, Q1 would present quite differently. Is this an ethical presentation, and should I be concerned with holding this stock? How does the balance sheet look? Because of my small position, I had planned on holding for a couple of years and riding out the volatility, but of course it's a shame to lose the gain if they are not presenting the true picture, and the stock is weaker than it appears. Your opinion please. Thank-you.
Read Answer Asked by Kim on March 30, 2015
Q: What do you make of their latest financial report? Would you buy this stock now? Thank you.
Read Answer Asked by John on March 30, 2015
Q: I know you like Knight Therapeutics. Stock has been hit quite hard recently, and currently is trading around $8. Do you think it's a good entry price here? Also is it a safe stock to hold in a RESP account? (My kids are quite young, so the money inside RESP won't be cashed for minimum 10 years.)Thanks for your great advice!
Read Answer Asked by Rebecca on March 26, 2015
Q: Hello, could we have your thoughts on the current valuation and prospects for Savaria. It is approaching 6 per cent of my portfolio which is pretty high for a company of this size I think. Thanks.
Read Answer Asked by Adam on March 24, 2015
Q: Mr. Dalsin has said in three different calls/interviews now that a dividend, by the company, is one of their milestones once they reach the 20-25 million EBITDA. Do you still consider the initiation of a dividend as being one of the strongest indicators of a company's strength?
Read Answer Asked by Kyle on March 23, 2015
Q: Hi Peter,

I have a small position in Biosyent. Admittedly it had a very good run in 2014, but has gone a bit silent in recent months despite strong numbers. Would you see this as normal consolidation or are there other issues at play. I'm a bit underwater and would appreciate your thoughts on whether to hold or to move on.

Thanks
Read Answer Asked by Greg on March 19, 2015
Q: In Johnathan Goodman's comments this morning, following release of their results, he indicated he will not rest until Knight realizes the same gains as Paladin (paraphrased). Do you see the possibility that this stock will go from $9 to $140 and was there anything in their year end results that gives a hint this is even remotely possible??
On another note, what happened to RMP Energy?
Thanks.
Read Answer Asked by Steven on March 19, 2015
Q: Hi Peter and team,

Patient Home Monitoring is a Canadian company but all or most of the business is in the US. Is the business model stable. Can you kindly let me know about the revenue and profit is stable as well. Is this a good buy because the company stock has triple in the last year. Thanks.
Read Answer Asked by Norwood on March 19, 2015
Q: Peter,
What are your thoughts on New Look's Q4 results? Earnings continue to grow, margins holding in around the 20% level. Decent dividend and despite the strong share appreciation, still seems to be 'under the radar' as no one has asked a question about the company in nearly a year. Valuation seems to be the big question mark and whether they can expand in Canada.
Thanks.
Read Answer Asked by Zach on March 18, 2015
Q: Can I have your thoughts on Lumenpulse. Thanks
Read Answer Asked by Leonard on March 18, 2015
Q: Would like to have your thoughts on new look eyeware. tks
Read Answer Asked by Albert on March 17, 2015
Q: Down on results today, is this a buying opportunity? Thanks
Read Answer Asked by richard on March 17, 2015
Q: Hello,
what do you think of guestlogix these days?
Luke
Read Answer Asked by luke on March 17, 2015
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!